Recombinant human growth hormone (rhGH) is effective in pubertal patients.
Recombinant human growth hormone (rhGH) therapy in a dose of 28-30 i.u./m2/week results in a significant and sustained improvement of height in most pubertal patients with growth retardation secondary to chronic renal insufficiency (CRI), dialysis or after renal transplantation (RTx). Long-term data indicate that rhGH therapy leads to a significant improvement in the final height of growth-retarded pubertal patients after renal transplantation.
Hokken-Koelega
A C
AC
Department of Pediatrics, Sophia Children's Hospital, Erasmus University, Rotterdam, The Netherlands.
D000293:Adolescent; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000601:surgery / Q000628:therapy; D016030:Kidney Transplantation; D011184:Postoperative Period; D006435:Renal Dialysis
D019382:Human Growth Hormone